Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.

Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) with...

Descripción completa

Detalles Bibliográficos
Autores: Bouzas, Cristina, Pastor, Rosario, García, Silvia, Monserrat-Mesquida, Margalida, Martínez-González, Miguel Ángel, 1957-, Salas Salvadó, Jordi, Corella Piquer, Dolores, Goday Arnó, Albert, Martínez, J. Alfredo, 1957-, Alonso Gómez, Ángel M., Fernández-Barceló, Olga, Vioque, Jesús, Romaguera, Dora, López Miranda, José, Estruch Riba, Ramon, Tinahones, Francisco J., Lapetra, José, Serra Majem, Lluís, Riquelme Gallego, Blanca, Martín Sánchez, Vicente, Pintó Sala, Xavier, Delgado Rodriguez, Miguel, Matía Martín, Pilar, Vidal i Cortada, Josep, Cardenas-Salas, Jersy-Jair, Daimiel, Lidia, Ros Rahola, Emilio, Toledo Atucha, Estefanía, Manzanares, Josep-Maria, Gonzalez Monge, Inmaculada, Muñoz Pérez, Miguel Ángel, Martinez-Urbistondo, Diego, Tojal Sierra, Lucas, Muñoz Bravo, Carlos, Miralles Gisbert, Salvador, Martin, Marian, García Ríos, Antonio, Castro-Barquero, Sara, Fernández García, José C., Santos Lozano, José Manuel, Basterra Gortari, F. Javier, Gutiérrez Carrasquilla, Liliana, Guillem Saiz, Patricia, Satorres, Alba, Abete, Itziar, Sorto Sanchez, Carolina, Díez Espino, Javier, Babio, Nancy, Fitó Colomer, Montserrat, Tur, Josep A.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/201013
Acceso en línea:https://hdl.handle.net/2445/201013
Access Level:acceso abierto
Palabra clave:Síndrome metabòlica
Diabetis
Glucagó
Pèptids
Inhibidors enzimàtics
Metabolic syndrome
Diabetes
Glucagon
Peptides
Enzyme inhibitors
Descripción
Sumario:Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m2; ∆ metformin: - 0.8(± 1.5) kg/m2; ∆ DPP-4I: - 0.6(± 1.3) kg/m2; ∆ GLP-1RA: - 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: -2.8(± 5.2) cm; ∆ metformin: - 2.6(± 15.2) cm; ∆ DPP-4I: - 2.1(± 4.8) cm; ∆ GLP-1RA: - 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.

Similares en LA Referencia